DMPI - DelMar Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
All numbers in thousands
Revenue6/30/20186/30/20176/30/20166/30/2015
Total Revenue----
Cost of Revenue----
Gross Profit----
Operating Expenses
Research Development7,132.9525,003.643,360.8782,555.754
Selling General and Administrative4,041.7113,317.1892,853.142,168.899
Non Recurring----
Others----
Total Operating Expenses11,174.6638,405.9236,591.9454,724.653
Operating Income or Loss-11,174.663-8,405.923-6,591.945-4,724.653
Income from Continuing Operations
Total Other Income/Expenses Net36.351324.159-2,272.919376.886
Earnings Before Interest and Taxes-11,174.663-8,405.923-6,591.945-4,724.653
Interest Expense----2.091
Income Before Tax-11,138.312-8,081.764-8,864.864-4,347.767
Income Tax Expense----
Minority Interest----
Net Income From Continuing Ops-11,138.312-8,081.764-8,864.864-4,347.767
Non-recurring Events
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income-11,138.312-8,081.764-8,864.864-4,347.767
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares-11,314.548-8,872.218-9,103.19-4,347.767